Yoshikazu Takada

Galectin-3 binds to the RGD-binding site in a glycan-independent manner and to the allosteric site and activates integrins αvβ3, αIIbβ3, and α5β1

This study shows Galectin-3 binds to integrins αvβ3, αIIbβ3, and α5β1 in a glycan-independent manner and activates them through two distinct sites, with implications for inflammation and thrombosis.

Ivermectin binds to the allosteric site (site 2) and inhibits allosteric integrin activation by pro-inflammatory cytokines.

This study shows ivermectin binds to the allosteric site 2 of integrins and inhibits their activation by pro-inflammatory cytokines, similar to anti-inflammatory cytokines.

The EC2 domains of tetraspanins CD9, CD81, and CD151 bind to the allosteric site of integrins (site 2) and activate integrins αvβ3, α5β1 and α4β1 in a biphasic manner.

FGF2 binds to the allosteric site (site 2) and activates integrin αIIbβ3 and FGF1 binds to site 2 but suppresses integrin activation by FGF2: A potential mechanism of anti-thrombotic action of FGF1.

This study shows FGF2 activates integrin αIIbβ3 via site 2, while FGF1 binds site 2 but inhibits FGF2-induced activation, suggesting FGF1's anti-thrombotic mechanism.

FGF2 binds to the allosteric site (site 2) and activates αvβ3 integrin and FGF1 binds to site 2 but suppresses integrin activation by FGF2: a potential mechanism of anti-inflammatory action of FGF1

This study shows FGF2 activates αvβ3 integrin via site 2, while FGF1 binds site 2 but suppresses integrin activation, suggesting FGF1's anti-inflammatory action is through blocking site 2.